S
Sonal Srivastava
Researcher at Central Drug Research Institute
Publications - 12
Citations - 365
Sonal Srivastava is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: Cancer cell & Cancer. The author has an hindex of 7, co-authored 12 publications receiving 212 citations.
Papers
More filters
Journal ArticleDOI
Global occurrence of deoxynivalenol in food commodities and exposure risk assessment in humans in the last decade: a survey.
TL;DR: The present review indicates that the current exposure levels of DON might pose a health risk for the consumers, especially in growing children, necessitating to take vigilant steps to guarantee food safety.
Journal ArticleDOI
Salinomycin: A new paradigm in cancer therapy.
TL;DR: The potential of salinomycin to eliminate both cancer stem cells and therapy-resistant cancer cells may characterize the compound as a novel and an efficient chemotherapeutic drug.
Journal ArticleDOI
Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells.
Jayant Dewangan,Divya Tandon,Sonal Srivastava,Ajeet Kumar Verma,Ashok Yapuri,Srikanta Kumar Rath +5 more
TL;DR: Study suggests that Salinomycin and RES offer a novel combination approach for the treatment of breast cancer.
Journal ArticleDOI
Salinomycin inhibits breast cancer progression via targeting HIF-1α/VEGF mediated tumor angiogenesis in vitro and in vivo.
TL;DR: It is suggested that SAL inhibits VEGF induced angiogenesis and breast cancer growth via interrupting HIF-1α/VEGF signalling and could be used as a promising antiangiogenic agent for breast cancer treatment.
Journal ArticleDOI
Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction.
Jayant Dewangan,Sonal Srivastava,Sakshi Mishra,Prabhash K. Pandey,Aman Divakar,Srikanta Kumar Rath +5 more
TL;DR: The overall findings suggest that Chetomin inhibited the growth of human TNBC cells by caspase-dependent apoptosis and modulation of PI3K/mTOR signalling and could be used as a novel chemotherapeutic agent for the treatment ofhuman TNBC in future.